TLDR No single treatment is clearly effective for central serous chorioretinopathy.
The network meta-analysis on interventions for central serous chorioretinopathy (CSC) included 25 studies with 1,098 participants and found that the overall quality of evidence was low due to small sample sizes and poor reporting. Treatments like anti-VEGF agents and photodynamic therapy (PDT) were compared, with PDT showing some promise in improving visual acuity and reducing recurrence. However, no single treatment demonstrated overwhelming efficacy, partly due to CSC's natural tendency to resolve spontaneously. The study highlighted the need for more high-quality, large-scale trials to determine the most effective interventions for CSC.
87 citations,
December 2015 in “Cochrane library” No single treatment is clearly effective for central serous chorioretinopathy.
22 citations,
August 2015 in “Cochrane Database of Systematic Reviews” The study aims to find the best treatment for central serous chorioretinopathy by comparing various options.
59 citations,
April 2011 in “Retina-the Journal of Retinal and Vitreous Diseases” Finasteride may help treat chronic CSC, improving vision.
13 citations,
February 2019 in “Türk oftalmoloji dergisi” New treatments for chronic central serous chorioretinopathy show promise in preventing permanent vision loss.
22 citations,
August 2015 in “Cochrane Database of Systematic Reviews” The study aims to find the best treatment for central serous chorioretinopathy by comparing various options.
15 citations,
April 2016 in “Eye” Finasteride effectively treats central serous chorioretinopathy.
14 citations,
September 2019 in “Eye” Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.
April 2024 in “International journal of molecular sciences” Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.
